antabio, Author at Antabio

Antabio is seeking a Laboratory Technician to join our discovery biology team

15th February 2019

Antabio is seeking a Laboratory Technician to join our discovery biology team. The qualified individual should be an enthusiastic biologist/technician with scientific understanding and laboratory skills. Previous biotechnology or pharmaceutical experience is a plus, but not essential; however, the candidate must show a proven ability to work effectively within a multi-disciplinary team environment and should be self-motivated.

Marc Lemonnier appointed at the Scientific Advisory Board of JPIAMR

22nd January 2019

We are pleased to announce that Antabio’s CEO Marc Lemonnier has been appointed as a new member of the Scientific Advisory Board (SAB) of JPIAMR.

ANTABIO Completes € 12.5M Series A

12th July 2018

New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017.

First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program

23rd March 2018No Comments

Antabio announces publication of a manuscript in Antimicrobial Agents and Chemotherapy: Discovery of a Novel Metallo-ß-Lactamase Inhibitor, which can Potentiate Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae (currently available as an ePublication – https://www.ncbi.nlm.nih.gov/pubmed/29530861). This is the first publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor…

ANTABIO Announces Key Executive Appointments

5th January 2018

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of four highly successful and accomplished biotech executives to the management team. These appointments come soon after the first closing of Antabio’s Series A financing round and notification that Antabio has been selected as one of 18 out of 368 international candidates for a CARB-X subsidy award of up to $8,9 million.

ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections

16th October 2017

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.

ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients

25th July 2017

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-X from a group of 368 applicants worldwide and is part of the first cohort that includes companies from Continental Europe.

Marc Lemonnier elected at the Board of the BEAM Alliance

19th January 2017

Antabio’s CEO Marc Lemonnier has been elected at the Board of Directors of the BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) further to the alliance’s Extraordinary General Assembly held in Paris on 20 December 2016. The BEAM Alliance represents European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.

Antabio receives the BIOVISION 2016 Investor Conference Biotech Award

14th April 2016

Antabio announced today that the company has received the BIOVISION Investment Conference 2016 Award in the biotech category. The BIOVISION Investor Conference was created to accelerate the fundraising process of Biotech, Medtech, e-health and environmental health start-ups by putting them in direct contact with potential business and development partners.

Antabio announces further progress towards the treatment of antibiotic-resistant infections

7th March 2016

Antabio announced today that it has achieved two milestones in its antibacterial drug discovery collaborations with the Wellcome Trust. These results release a further €3.1 million from the Seeding Drug Discovery Awards received by Antabio. The first collaboration (“the MBLi program”) began in February 2013 when the Wellcome Trust awarded Antabio €4.7 million to fund the discovery of a novel, safe and efficacious inhibitor of bacterial metallo beta-lactamases (MBLs).

Author: antabio